Market capitalization | €90.00k |
Enterprise Value | €-1.84m |
PER (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | -0.06 |
P/S ratio (TTM) P/S ratio | 0.00 |
P/B ratio (TTM) P/B ratio | 0.08 |
Sales growth (TTM) Sales growth | 25.30% |
Turnover (TTM) Turnover | €32.25m |
EBIT (operating result TTM) EBIT | €4.78m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
1 Analyst has issued a forecast Biofrontera:
1 Analyst has issued a forecast Biofrontera:
Dec '23 |
+/-
%
|
||
Turnover | 32 32 |
25%
25%
|
|
Gross income | 26 26 |
24%
24%
|
|
EBITDA | 5.57 5.57 |
138%
138%
|
EBIT (operating result) EBIT | 4.78 4.78 |
200%
200%
|
Net profit | -0.37 -0.37 |
99%
99%
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Biofrontera AG operates as a biopharmaceutical company, which engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products are used for the treatment of chronic, antihistamine refractory urticaria and migraine prophylaxis. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.
Head office | Germany |
CEO | Hermann Lübbert |
Employees | 95 |
Founded | 1997 |
Website | biofrontera.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.